================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JUNE 22, 2000
-------------
VION PHARMACEUTICALS, INC.
--------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26534 13-3671221
-------- ------- ----------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
4 Science Park, New Haven, CT 06511
----------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 498-4210
--------------
Not Applicable
--------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
<PAGE>
Item 5. Other Events
On June 22, 2000, Vion Pharmaceuticals, Inc. (the "Company") issued a
press release, filed herewith as Exhibit 99.1, relating to an interim evaluation
of a Phase III randomized trial of Promycin(R) (porfiromycin) combined with
radiotherapy versus radiotherapy alone in patients with non-resectable head and
neck cancer. The Company has been informed by its licensee, Boehringer Ingelheim
(BI), Ingelheim, Germany, that the interim evaluation did not meet the
pre-determined criteria which would warrant continuation of accrual.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
99.1 Press release issued June 22, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VION PHARMACEUTICALS, INC.
Date: June 22, 2000 By: /s/ Alan Kessman
-----------------------------------------
Name: Alan Kessman
Title: President and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
-------------
99.1 Press release issued June 22, 2000.
